智通财经网·2025-09-12 06:07Core Viewpoint - Nocera Health (09969) experienced a significant stock increase of 12.96%, reaching HKD 19, with a trading volume of HKD 406 million following the approval of its drug Ibrutinib for a new indication in Singapore [1] Group 1: Company Developments - Nocera Health announced on September 8 that Ibrutinib has received approval from the Health Sciences Authority (HSA) of Singapore for the treatment of relapsed/refractory marginal zone lymphoma (R/R MZL) in adult patients, marking the second indication approved in Singapore [1] - The company reported a revenue of CNY 731 million for the first half of 2025, representing a year-on-year growth of 74.3%, with sales of its core product Ibrutinib reaching CNY 637 million, a 52.8% increase year-on-year [1] - The approval of Ibrutinib for the new indication of first-line CLL/SLL has been included in the 2025 CSCO lymphoma guidelines with a level 1 recommendation, enhancing its market potential in hematological malignancies [1] Group 2: Market and Product Insights - Ibrutinib has already been approved in China for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), relapsed/refractory mantle cell lymphoma (R/R MCL), and relapsed/refractory marginal zone lymphoma (R/R MZL), all of which are covered by the national medical insurance [1] - The company is expanding its product portfolio with the approval of its second innovative drug, Tansimab, in May 2025 for use in combination with Lenalidomide for the treatment of relapsed/refractory DLBCL, further enriching its commercial product matrix [1]